PL4219687T3 - Metody izolacji, hodowli i inżynierii genetycznej populacji komórek odpornościowych na potrzeby terapii adopcyjnej - Google Patents

Metody izolacji, hodowli i inżynierii genetycznej populacji komórek odpornościowych na potrzeby terapii adopcyjnej

Info

Publication number
PL4219687T3
PL4219687T3 PL23164036.8T PL23164036T PL4219687T3 PL 4219687 T3 PL4219687 T3 PL 4219687T3 PL 23164036 T PL23164036 T PL 23164036T PL 4219687 T3 PL4219687 T3 PL 4219687T3
Authority
PL
Poland
Prior art keywords
culturing
isolating
methods
immune cell
cell populations
Prior art date
Application number
PL23164036.8T
Other languages
English (en)
Inventor
Chris RAMSBORG
Mark L Bonyhadi
Calvin Chan
Pascal BEAUCHESNE
Original Assignee
Juno Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53055126&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4219687(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Juno Therapeutics, Inc. filed Critical Juno Therapeutics, Inc.
Publication of PL4219687T3 publication Critical patent/PL4219687T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/04—Cell isolation or sorting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Sustainable Development (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
PL23164036.8T 2014-04-23 2015-04-23 Metody izolacji, hodowli i inżynierii genetycznej populacji komórek odpornościowych na potrzeby terapii adopcyjnej PL4219687T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983415P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
PL4219687T3 true PL4219687T3 (pl) 2024-10-28

Family

ID=53055126

Family Applications (1)

Application Number Title Priority Date Filing Date
PL23164036.8T PL4219687T3 (pl) 2014-04-23 2015-04-23 Metody izolacji, hodowli i inżynierii genetycznej populacji komórek odpornościowych na potrzeby terapii adopcyjnej

Country Status (21)

Country Link
US (8) US11400115B2 (pl)
EP (4) EP4219687B1 (pl)
JP (5) JP6759187B2 (pl)
KR (3) KR102447958B1 (pl)
CN (3) CN106459917B (pl)
AU (3) AU2015249554B2 (pl)
BR (1) BR112016024579A2 (pl)
CA (1) CA2946312A1 (pl)
DK (1) DK4219687T3 (pl)
ES (2) ES2995052T3 (pl)
FI (1) FI4219687T3 (pl)
IL (5) IL292038B2 (pl)
MA (2) MA39867A (pl)
MX (2) MX382541B (pl)
PH (1) PH12016502112A1 (pl)
PL (1) PL4219687T3 (pl)
PT (1) PT4219687T (pl)
RU (1) RU2763795C2 (pl)
SA (1) SA516380118B1 (pl)
SG (1) SG11201608862SA (pl)
WO (1) WO2015164675A1 (pl)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US10228312B2 (en) 2012-02-23 2019-03-12 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
IL280738B (en) 2014-04-16 2022-07-01 Juno Therapeutics Gmbh Methods, kits and device for increasing cell populations
MA39867A (fr) 2014-04-23 2017-03-01 Juno Therapeutics Inc Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
CN106062185A (zh) * 2014-04-24 2016-10-26 美天旎生物技术有限公司 用于自动生成遗传修饰的t细胞的方法
KR20170078619A (ko) * 2014-09-17 2017-07-07 더 존스 홉킨스 유니버시티 항원-특이적 t 세포 식별, 농축, 및/또는 증식을 위한 시약 및 방법
FI3757206T3 (fi) 2014-11-05 2024-06-19 Juno Therapeutics Inc Menetelmiä transduktoimiseksi ja solun prosessoimiseksi
US11896614B2 (en) 2015-04-17 2024-02-13 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
JP6890831B2 (ja) 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
SG10201912978PA (en) 2015-07-21 2020-02-27 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US20170119820A1 (en) 2015-07-31 2017-05-04 Regents Of The University Of Minnesota Modified cells and methods of therapy
WO2017068425A1 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
CA3002745A1 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
RU2021134624A (ru) * 2015-10-22 2022-03-15 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
EP3397755B1 (en) * 2015-12-28 2024-11-06 Novartis AG Methods of making chimeric antigen receptor -expressing cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
IL297238B2 (en) 2016-01-15 2024-08-01 American Gene Tech Int Inc Methods and preparations for gamma-delta T-cell activation
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
US10767183B2 (en) 2016-03-09 2020-09-08 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
MA43759A (fr) 2016-03-16 2018-11-28 Jason Connor Procédés de conception adaptative d'un régime de traitement et traitements associés
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
IL300730A (en) 2016-07-08 2023-04-01 American Gene Tech Int Inc Pre-HIV vaccine and immunotherapy
US11583562B2 (en) 2016-07-21 2023-02-21 American Gene Technologies International Inc. Viral vectors for treating Parkinson's disease
WO2018049420A1 (en) 2016-09-12 2018-03-15 Juno Therapeutics, Inc. Perfusion bioreactor bag assemblies
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
WO2018102761A1 (en) * 2016-12-02 2018-06-07 City Of Hope Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
JP2019536461A (ja) * 2016-12-05 2019-12-19 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法のための操作細胞の産生
JP7061125B2 (ja) 2016-12-16 2022-04-27 ダイアグノロジックス・エルエルシー 浮力による分離方法およびシステム
MX2019010171A (es) 2017-02-27 2019-10-15 Juno Therapeutics Inc Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
CN110913690A (zh) 2017-03-14 2020-03-24 朱诺治疗学股份有限公司 用于低温储存的方法
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
KR102737836B1 (ko) 2017-04-03 2024-12-03 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 페닐케톤뇨증을 치료하기 위한 조성물 및 방법
AU2018251188A1 (en) 2017-04-14 2019-10-31 Juno Therapeutics, Inc. Methods for assessing cell surface glycosylation
MA49288A (fr) * 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
JP2020522489A (ja) 2017-06-02 2020-07-30 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法を用いる処置のための製造物品および方法
EP3634427A1 (en) 2017-06-07 2020-04-15 Seattle Genetics, Inc. T cells with reduced surface fucosylation and methods of making and using the same
JP2020524996A (ja) 2017-06-16 2020-08-27 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド ヒトガンマデルタｔ細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2019011879A1 (en) 2017-07-09 2019-01-17 Rainer Henning THERAPEUTIC AGENT FOR THE TREATMENT OF CAPILLARY LEAK SYNDROME
AU2018304543A1 (en) * 2017-07-21 2020-02-13 Berkeley Lights, Inc. Antigen-presenting synthetic surfaces, covalently functionalized surfaces, activated T cells, and uses thereof
MX2020001491A (es) * 2017-08-09 2020-08-06 Juno Therapeutics Inc Metodos y composiciones para preparar celulas geneticamente modificadas.
WO2019032927A1 (en) 2017-08-09 2019-02-14 Juno Therapeutics, Inc. METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF
CN115216450A (zh) * 2017-09-01 2022-10-21 隆萨沃克斯维尔股份有限公司 端到端细胞治疗自动化
WO2019051335A1 (en) 2017-09-07 2019-03-14 Juno Therapeutics, Inc. METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY
US20200331975A1 (en) * 2017-10-20 2020-10-22 Institut Curie Dap10/12 based cars adapted for rush
EP4512823A3 (en) 2017-11-01 2025-05-14 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
BR112020008565A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc processo para a produção de uma composição de célula t
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR20200095487A (ko) 2017-11-10 2020-08-10 주노 쎄러퓨티크스 인코퍼레이티드 폐쇄-시스템 극저온 용기
CA3083949A1 (en) * 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
AU2018379094B2 (en) 2017-12-08 2025-09-25 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
CN112041430A (zh) 2017-12-08 2020-12-04 朱诺治疗学股份有限公司 用于培养细胞的无血清培养基配制品及其使用方法
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
EP3773622A4 (en) * 2018-03-27 2021-12-01 American Gene Technologies International Inc. METHODS OF PREPARING GENETICALLY MODIFIED LYMPHOCYTES
JP7447011B2 (ja) * 2018-03-28 2024-03-11 ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用
US12473532B2 (en) 2018-05-10 2025-11-18 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3100386A1 (en) 2018-05-23 2019-11-28 National University Of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
CN110643577A (zh) * 2018-06-26 2020-01-03 深圳市北科生物科技有限公司 基于机械臂的全自动细胞培养方法及其系统
WO2020033916A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
AU2019339464A1 (en) 2018-09-11 2021-03-25 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
JP7396777B2 (ja) 2018-09-28 2023-12-12 オクタン バイオテック インコーポレーテッド 磁気分離
CN113227358A (zh) 2018-10-31 2021-08-06 朱诺治疗学有限公司 选择并刺激细胞的方法及用于所述方法的设备
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
MX2021005021A (es) 2018-11-06 2021-08-11 Juno Therapeutics Inc Proceso para producir celulas t geneticamente modificadas.
KR20210104713A (ko) 2018-11-16 2021-08-25 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
BR112021010120A2 (pt) 2018-11-30 2021-08-31 Juno Therapeutics, Inc. Métodos para dosagem e tratamento de malignidades celulares em terapia celular adotiva
FI3886875T3 (fi) 2018-11-30 2024-07-23 Juno Therapeutics Inc Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
CA3123314A1 (en) 2018-12-21 2020-06-25 Octane Biotech Inc. Carousel for modular biologic production units
WO2020132177A1 (en) 2018-12-21 2020-06-25 Lonza Walkersville, Inc. Automated production of viral vectors
TWI732357B (zh) * 2018-12-27 2021-07-01 財團法人工業技術研究院 細胞培養裝置及方法
CA3127261A1 (en) * 2019-01-29 2020-08-06 Gpb Scientific, Inc. Cell populations with improved production and therapeutic characteristics
US11773365B2 (en) 2019-02-08 2023-10-03 Lonza Walkersville, Inc. Cell concentration methods and devices for use in automated bioreactors
SG11202109057XA (en) 2019-03-05 2021-09-29 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
DE102019108125B4 (de) * 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
US20220170908A1 (en) * 2019-03-26 2022-06-02 Anton Wyss-Coray Compositions and methods for characterizing and treating alzheimers disease
WO2020210508A1 (en) 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
AR118859A1 (es) * 2019-05-08 2021-11-03 Neon Therapeutics Inc Composiciones y métodos de fabricación de células t
WO2020236654A1 (en) 2019-05-17 2020-11-26 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
WO2020236850A1 (en) * 2019-05-20 2020-11-26 Immunovalent Therapeutics Inc. Solid phase devices and methods of use for purifying and quantifying tissue-specific leukocytes
KR20220034782A (ko) 2019-06-12 2022-03-18 주노 쎄러퓨티크스 인코퍼레이티드 세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
CN110358734B (zh) * 2019-06-13 2020-08-25 首都医科大学宣武医院 以Tcm为主要效应成分的CAR-T制备方法及其应用
CA3144450A1 (en) 2019-06-26 2020-12-30 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
CA3148769A1 (en) 2019-07-30 2021-02-04 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
WO2021041994A2 (en) 2019-08-30 2021-03-04 Juno Therapeutics, Inc. Machine learning methods for classifying cells
CA3158797A1 (en) 2019-10-24 2021-04-29 Octane Biotech Inc. Cell culture chamber with improved cell-contacting surfaces
BR112022008023A2 (pt) 2019-10-30 2022-07-12 Juno Therapeutics Gmbh Dispositivos de seleção e/ou estimulação de células e métodos de uso
EP4055383A1 (en) 2019-11-05 2022-09-14 Juno Therapeutics, Inc. Methods of determining attributes of therapeutic t cell compositions
EP4058563A4 (en) 2019-11-11 2023-12-06 Lonza Walkersville, Inc. QUALITY CONTROL PROCEDURES FOR AUTOMATED CELL PROCESSING
EP4070097A1 (en) 2019-12-06 2022-10-12 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
EP4069816A1 (en) * 2020-01-10 2022-10-12 Lonza Walkersville, Inc. Filter apparatus and method for purifying biological processes and cell populations
BR112022014501A2 (pt) 2020-01-24 2022-09-20 Juno Therapeutics Inc Métodos para dosagem e tratamento de linfoma folicular e linfoma de zona marginal em terapia celular adotiva
IL295384A (en) 2020-02-12 2022-10-01 Juno Therapeutics Inc Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
IL295381A (en) 2020-02-12 2022-10-01 Juno Therapeutics Inc bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof
AU2021251265A1 (en) 2020-04-10 2022-11-03 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
WO2021222227A1 (en) * 2020-04-27 2021-11-04 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting cd127 and use thereof
EP4150057A2 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
EP4150640A1 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
AU2021305084A1 (en) 2020-07-07 2023-02-02 Cancure, Llc MIC antibodies and binding agents and methods of using the same
US20240392226A1 (en) * 2020-10-12 2024-11-28 Life Technologies As Magnetic particle processing systems for use with biological cells and related methods
US12415982B2 (en) 2020-10-23 2025-09-16 Applied Materials, Inc. Automated closed system for cell therapy manufacturing
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
EP4314814A1 (en) 2021-03-22 2024-02-07 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
BR112023019847A2 (pt) 2021-03-29 2023-11-07 Juno Therapeutics Inc Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
CN113388042B (zh) * 2021-06-28 2022-02-01 北京鼎成肽源生物技术有限公司 一种重组蛋白、重组表达载体、重组细胞和nk细胞激活磁珠及其制备方法和应用
EP4381050A4 (en) * 2021-08-06 2025-10-08 Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute T CELL MANUFACTURING PROCESSES
WO2023021571A1 (ja) * 2021-08-17 2023-02-23 日揮株式会社 演算装置、制御装置、培養システム、及び培養システムの設計方法
CN117466983A (zh) * 2022-02-14 2024-01-30 西南大学 链霉亲和素第27位丝氨酸突变的突变蛋白s27l及其应用
CN114507274B (zh) * 2022-02-14 2023-08-25 西南大学 可逆结合生物素的链霉亲和素突变蛋白及其应用
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
KR20250011945A (ko) 2022-05-17 2025-01-22 우모자 바이오파마 인코포레이티드 바이러스 입자의 제조
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
EP4543923A1 (en) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
TW202434735A (zh) 2022-11-04 2024-09-01 美商烏莫賈生物製藥股份有限公司 展示黏著分子融合的顆粒
IL320495A (en) 2022-11-04 2025-06-01 Umoja Biopharma Inc Construction of polynucleotide vectors and related viral methods
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
EP4630782A1 (en) 2022-12-09 2025-10-15 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
EP4658675A1 (en) 2023-02-03 2025-12-10 C3S2 GmbH Methods for non-viral manufacturing of engineered immune cells
KR20260005874A (ko) 2023-02-28 2026-01-12 주노 쎄러퓨티크스 인코퍼레이티드 전신 자가면역 질환을 치료하기 위한 세포 요법
CN116640192B (zh) * 2023-04-12 2024-08-02 西南大学 链霉亲和素突变体StrepTactin的Y43A突变蛋白及其应用
CN121311765A (zh) 2023-04-18 2026-01-09 朱诺治疗学股份有限公司 评估治疗性细胞组合物的效力的细胞毒性测定
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
WO2024238153A1 (en) 2023-05-15 2024-11-21 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
KR20260026101A (ko) 2023-05-23 2026-02-25 주노 쎄러퓨티크스 인코퍼레이티드 T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법
EP4715044A1 (en) 2023-07-11 2026-03-25 Chongqing Precision Biotech Co., Ltd. Cell treatment product preparation process and use thereof
WO2025072081A1 (en) * 2023-09-25 2025-04-03 The Cleveland Clinic Foundation Enriched t-cell populations
WO2025145121A1 (en) * 2023-12-31 2025-07-03 Trenchant BioSystems, Inc. Functionally closed cell processing system
WO2025231174A1 (en) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Manufacturing viral particles
WO2025235604A1 (en) 2024-05-08 2025-11-13 Umoja Biopharma, Inc. Fusion protein for use as immune cell engager
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
US20260061053A1 (en) 2024-08-28 2026-03-05 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
FR2540122B1 (fr) 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (pl) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
WO1990007380A2 (en) 1988-12-28 1990-07-12 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
AU650085B2 (en) 1990-11-13 1994-06-09 Immunex Corporation Bifunctional selectable fusion genes
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
ES2240962T3 (es) 1993-06-04 2005-10-16 The United States Of America As Represented By The Secretary Of The Navy Metodo para estimular selectivamente la proliferacion de celulas t.
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1997011183A1 (en) 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
US5801115A (en) 1995-09-05 1998-09-01 Kataleuna Gmbh Catalyst composition and methods for using and preparing same
US5773224A (en) * 1996-02-12 1998-06-30 Grandics; Peter Immunoselection system for cell elution
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2000043551A1 (en) 1999-01-26 2000-07-27 Cornell Research Foundation, Inc. Determining viral load in double negative t cells
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
ATE450544T1 (de) 2002-03-01 2009-12-15 Volker A Erdmann Streptavidin-bindungspeptid
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7754155B2 (en) 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
AU2003277153A1 (en) 2002-09-27 2004-04-19 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
KR101348472B1 (ko) 2002-10-17 2014-01-07 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US7795024B2 (en) 2003-05-02 2010-09-14 Insception Bioscience, Inc. Apparatus and methods for amplification of blood stem cell numbers
US7943393B2 (en) 2003-07-14 2011-05-17 Phynexus, Inc. Method and device for extracting an analyte
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
AU2004292131A1 (en) 2003-11-20 2005-06-02 Biosensor Applications Sweden (Publ) Mixture of at least two different antibodies specific for predetermined antigens and use of the mixture
SE0400181D0 (sv) 2004-01-29 2004-01-29 Gyros Ab Segmented porous and preloaded microscale devices
WO2005121798A1 (en) 2004-06-03 2005-12-22 Meso Scale Technologies, Llc Methods and apparatuses for conducting assays
US20110098184A1 (en) 2004-10-15 2011-04-28 Day Anthony G Competitve differntial screeing
ES2766123T3 (es) 2004-12-10 2020-06-11 Peter Maccallum Cancer Inst Métodos y composiciones para inmunoterapia adoptiva
US20060252087A1 (en) 2005-01-18 2006-11-09 Biocept, Inc. Recovery of rare cells using a microchannel apparatus with patterned posts
EP1891113A2 (en) 2005-06-02 2008-02-27 AstraZeneca AB Antibodies directed to cd20 and uses thereof
US7855057B2 (en) 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
WO2007117602A2 (en) * 2006-04-07 2007-10-18 Biogen Idec Ma Inc. Isolation and use of human regulatory t cells
US20080085532A1 (en) 2006-09-18 2008-04-10 Jorn Gorlach Method for determining the immune status of a subject
WO2008053973A1 (fr) 2006-11-02 2008-05-08 Kyowa Medex Co., Ltd. Procédé d'essai immunologique d'un composant à mesurer
EP2518193A3 (en) 2006-11-15 2013-01-23 Invitrogen Dynal AS Methods for reversibly binding a biotin compound to a support
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
CN101226118B (zh) 2007-01-19 2010-06-16 中国医学科学院肿瘤研究所 一种兼容免疫荧光分析的细胞化学染色方法及其用途
DK2141997T3 (da) 2007-03-30 2013-02-11 Sloan Kettering Inst Cancer Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
EP2178916B1 (en) 2007-07-31 2014-12-17 Regeneron Pharmaceuticals, Inc. Human antibodies to human cd20 and method of using thereof
US8747290B2 (en) * 2007-12-07 2014-06-10 Miltenyi Biotec Gmbh Centrifuge for separating a sample into at least two components
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
KR20180090396A (ko) 2008-01-18 2018-08-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법
US9090875B2 (en) 2008-01-29 2015-07-28 Fred Hutchinson Cancer Research Center Identifcation of CD8+ T cells that are CD161hi and/or IL18Rαhi and have rapid drug efflux capacity
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
US20110070581A1 (en) 2009-04-27 2011-03-24 Amit Gupta Separation of Leukocytes
EP2363501A1 (en) 2010-03-02 2011-09-07 Universitätsklinikum Hamburg-Eppendorf Method for isolating target cells
US9678061B2 (en) 2010-08-06 2017-06-13 Ludwig-Maximilians-Universität München Identification of T cell target antigens
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
HUE028452T2 (en) 2010-12-14 2016-12-28 Glaxosmithkline Biologicals Sa Mycobacterium antigenic preparations
JP5937015B2 (ja) 2010-12-16 2016-06-22 株式会社明治 遅延型過敏症軽減剤
AU2012230780B2 (en) 2011-03-23 2016-10-27 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
DK2837680T3 (da) 2011-07-01 2020-04-27 Amgen Inc Mammaliacellekultur
EP3418295B1 (en) 2011-07-18 2020-09-02 IBA GmbH Method of reversibly staining a target cell
US9353161B2 (en) * 2011-09-13 2016-05-31 Uti Limited Partnership Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins
WO2013062365A2 (ko) * 2011-10-26 2013-05-02 국립암센터 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물
US9447194B2 (en) 2012-02-13 2016-09-20 Seattle Children's Hospital Bispecific chimeric antigen receptors and encoding polynucleotides thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
US10228312B2 (en) 2012-02-23 2019-03-12 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
CN104411819B (zh) * 2012-06-11 2019-05-10 威尔逊沃夫制造公司 用于过继细胞疗法的改进的细胞培养方法
WO2013192294A1 (en) 2012-06-20 2013-12-27 Boston 3T Biotechnologies, Inc. Cellular therapies for treating and preventing cancers and other immune system disorders
EP3584256A1 (en) * 2012-07-13 2019-12-25 The Trustees Of The University Of Pennsylvania Methods of assessing the suitability of transduced t cells for administration
EA201992742A3 (ru) 2012-07-13 2020-12-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Применение cart19 для истощения нормальных b-клеток для индукции толерантности
PT3824905T (pt) 2012-08-20 2025-03-21 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapêutica celular
RU2648476C2 (ru) 2012-09-07 2018-03-26 Дженентек, Инк. Комбинированная терапия с использованием антитела против cd20 типа ii и селективного ингибитора bcl-2
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
US9599590B2 (en) 2012-10-12 2017-03-21 Sage Science, Inc. Side-eluting molecular fractionator
JP6475630B2 (ja) 2012-11-16 2019-02-27 イーベーアー ゲーエムベーハー ストレプトアビジン突然変異タンパク質およびそれらを使用する方法
DE112012007250B4 (de) 2012-12-20 2024-10-24 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
JP6450690B2 (ja) 2013-02-15 2019-01-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア キメラ抗原受容体及びその使用方法
RU2680010C2 (ru) 2013-02-26 2019-02-14 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы иммунотерапии
PT2981607T (pt) 2013-04-03 2020-11-20 Memorial Sloan Kettering Cancer Center Geração eficaz de células t direcionadas a tumores, derivadas de células estaminais pluripotentes
ES2828982T3 (es) 2013-05-14 2021-05-28 Univ Texas Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
CN103305464B (zh) * 2013-06-05 2015-04-15 南昌大学 直接分离cd4+和cd8+淋巴细胞的方法
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
KR20230007559A (ko) 2013-12-20 2023-01-12 프레드 허친슨 캔서 센터 태그된 키메라 이펙터 분자 및 그의 리셉터
PL3129470T3 (pl) 2014-04-07 2021-11-29 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
MY185678A (en) 2014-04-10 2021-05-30 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Drug related transgene expression
IL280738B (en) 2014-04-16 2022-07-01 Juno Therapeutics Gmbh Methods, kits and device for increasing cell populations
MA39867A (fr) * 2014-04-23 2017-03-01 Juno Therapeutics Inc Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
EP3134437A1 (en) 2014-04-23 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
CN106062185A (zh) 2014-04-24 2016-10-26 美天旎生物技术有限公司 用于自动生成遗传修饰的t细胞的方法
RS60544B1 (sr) 2014-04-25 2020-08-31 Bluebird Bio Inc Poboljšani metodi za proizvodnju adoptivnih ćelijskih terapija
EP4008725A1 (en) 2014-05-02 2022-06-08 The Trustees of the University of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
JP6612340B2 (ja) 2014-10-15 2019-11-27 セージ サイエンス， インコーポレイテッド 核酸の自動化された加工処理および電気泳動による試料調製のための装置、方法およびシステム
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
FI3757206T3 (fi) 2014-11-05 2024-06-19 Juno Therapeutics Inc Menetelmiä transduktoimiseksi ja solun prosessoimiseksi
CN107206025A (zh) 2014-12-03 2017-09-26 朱诺治疗学股份有限公司 用于过继细胞治疗的方法和组合物
CN107429253B (zh) 2014-12-05 2021-11-05 希望之城公司 Cs1靶向性嵌合抗原受体修饰的t细胞
PL3230321T3 (pl) 2014-12-12 2020-03-31 Bluebird Bio, Inc. Chimeryczne receptory antygenowe bcma
EP4036109A3 (en) 2014-12-29 2022-10-12 Novartis AG Methods of making chimeric antigen receptor-expressing cells
DE102015205759A1 (de) 2015-03-31 2016-10-06 Henkel Ag & Co. Kgaa Mittel für keratinhaltige Fasern, enthaltend mindestens ein Copolymer auf Basis von Vinylpyrrolidon und mindestens ein Copolymer aus Basis von Acrylaten
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
IL254817B2 (en) 2015-04-08 2023-12-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
HK1256130A1 (zh) 2015-07-21 2019-09-13 City Of Hope 用於嵌合抗原受体和其他受体的表达的t细胞
SG10201912978PA (en) 2015-07-21 2020-02-27 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US20170119820A1 (en) 2015-07-31 2017-05-04 Regents Of The University Of Minnesota Modified cells and methods of therapy
WO2017027291A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
CA3002745A1 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
WO2017096329A1 (en) 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
WO2017156479A1 (en) 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
WO2017157505A1 (en) 2016-03-17 2017-09-21 Merck Patent Gmbh Method for purifying poloxamers
WO2017161353A1 (en) 2016-03-18 2017-09-21 Fred Hutchinson Cancer Researh Center Compositions and methods for cd20 immunotherapy
JP2019536461A (ja) 2016-12-05 2019-12-19 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法のための操作細胞の産生
EP3346001A1 (en) 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
AU2018251188A1 (en) 2017-04-14 2019-10-31 Juno Therapeutics, Inc. Methods for assessing cell surface glycosylation
CN107723275B (zh) 2017-10-20 2020-09-04 重庆精准生物技术有限公司 通用型car-t细胞及其制备方法和应用
EP4512823A3 (en) 2017-11-01 2025-05-14 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
IL295384A (en) 2020-02-12 2022-10-01 Juno Therapeutics Inc Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
IL295381A (en) 2020-02-12 2022-10-01 Juno Therapeutics Inc bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof

Also Published As

Publication number Publication date
IL248451A0 (en) 2016-11-30
WO2015164675A1 (en) 2015-10-29
MX2021005625A (es) 2021-08-11
BR112016024579A2 (pt) 2017-10-10
RU2016145424A3 (pl) 2018-12-12
US20170037369A1 (en) 2017-02-09
IL292038A (en) 2022-06-01
IL269440A (en) 2019-11-28
EP3134514B1 (en) 2019-09-18
US20230090176A1 (en) 2023-03-23
EP4219687A1 (en) 2023-08-02
KR20220136455A (ko) 2022-10-07
AU2015249554B2 (en) 2021-08-19
AU2024202424A1 (en) 2024-06-27
JP7675243B2 (ja) 2025-05-12
EP4450615A2 (en) 2024-10-23
AU2015249554A1 (en) 2016-11-03
NZ763754A (en) 2021-09-24
MX2016013747A (es) 2017-04-27
PH12016502112A1 (en) 2016-12-19
RU2016145424A (ru) 2018-05-23
AU2021209195A1 (en) 2021-08-19
US12208137B2 (en) 2025-01-28
US11400115B2 (en) 2022-08-02
MA39867A (fr) 2017-03-01
NZ763755A (en) 2021-09-24
EP4219687B1 (en) 2024-08-14
US20250387482A1 (en) 2025-12-25
SG11201608862SA (en) 2016-11-29
CA2946312A1 (en) 2015-10-29
IL313845A (en) 2024-08-01
KR20240149454A (ko) 2024-10-14
US12296010B2 (en) 2025-05-13
AU2021209195B2 (en) 2024-05-09
JP6759187B2 (ja) 2020-09-23
ES2759260T3 (es) 2020-05-08
MX382541B (es) 2025-03-13
JP7181910B2 (ja) 2022-12-01
EP3647412A1 (en) 2020-05-06
JP2024071445A (ja) 2024-05-24
US20250161449A1 (en) 2025-05-22
ES2995052T3 (en) 2025-02-05
JP2025108747A (ja) 2025-07-23
CN113046321A (zh) 2021-06-29
SA516380118B1 (ar) 2020-05-21
RU2763795C2 (ru) 2022-01-11
US20230190814A1 (en) 2023-06-22
CN106459917B (zh) 2021-03-09
KR20170020751A (ko) 2017-02-24
FI4219687T3 (fi) 2024-10-31
JP2021180686A (ja) 2021-11-25
EP4450615A3 (en) 2025-01-08
MA51794A (fr) 2020-05-06
US20250152712A1 (en) 2025-05-15
DK4219687T3 (da) 2024-10-28
JP2017514517A (ja) 2017-06-08
IL280743A (en) 2021-04-29
IL248451B (en) 2019-10-31
EP3134514A1 (en) 2017-03-01
NZ726346A (en) 2021-09-24
JP7503035B2 (ja) 2024-06-19
IL269440B (en) 2021-02-28
US20250161450A1 (en) 2025-05-22
KR102447958B1 (ko) 2022-09-27
JP2020156495A (ja) 2020-10-01
IL280743B (en) 2022-05-01
IL292038B2 (en) 2024-12-01
IL292038B1 (en) 2024-08-01
PT4219687T (pt) 2024-10-02
CN106459917A (zh) 2017-02-22
CN113046312A (zh) 2021-06-29
US20250121062A1 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
IL248451B (en) Methods for the isolation, culture and genetic engineering of immune cell populations for stress therapy
IL276593B (en) Improved methods for producing adoptive cell therapies
IL250072A0 (en) Transgenic cells for stress cell therapy
ZA201608303B (en) Methods for harvesting mammalian cell cultures
ZA201703083B (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy
SG11201701191WA (en) Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
HUE041497T2 (hu) Immunsejteken és patológiás sejteken egyaránt jelen lévõ antigént célzó génmódosított sejtek immunterápia célra
EP3119477A4 (en) Tumor-infiltrating lymphocytes for adoptive cell therapy
EP3124589A4 (en) Cell culture method and cell culture system
EP3118322A4 (en) Method for isolating and proliferating self-tumor antigen-specific cd8+ t cells
SG11201609916RA (en) Culture method and cell mass
SG11202004935UA (en) Cell culture methods
EP3162891A4 (en) Cultured cell differentiation promotion method and cultured cell differentiation promoter
SG11201702897WA (en) Cell culture bag and cell culture method
HUE066922T2 (hu) Sejttenyésztési eljárások
SG11202000811RA (en) Methods for activating immune cells
SG11201609269TA (en) Method of culturing cells
HK1238292A1 (en) Engineered cells for adoptive cell therapy
AU2015902675A0 (en) Adoptive t cell therapy
AU2014902203A0 (en) Method of producing cells for adoptive cell transfer